GTC
PDSB icon

Ghost Tree Capital’s PDS Biotechnology PDSB Stock Holding History

Ghost Tree Capital’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-50,000
Closed -$820K – 54
2018
Q3 		$820K Buy
50,000
+12,460
+33% +$224K 0.17% 50
2018
Q2 		$773K Buy
+37,540
New +$783K 0.23% 40

Other funds holding PDSB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Ghost Tree Capital's PDSB Position: Q4 2018 in Review

Ghost Tree Capital sold out of PDS Biotechnology (PDSB) in Q4 2018, closing a stake of 50,000 shares — an estimated $820K sold.

Ghost Tree Capital first reported a position in PDSB in Q2 2018 and held it in 2 quarters. The position peaked at $820K in Q3 2018. 31 funds tracked by Wall St. Rank hold PDSB as of Q4 2018.

  • Ghost Tree Capital reported no remaining PDS Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Ghost Tree Capital sold 50,000 PDS Biotechnology shares in Q4 2018, an estimated $820K.
  • Ghost Tree Capital first reported a position in PDS Biotechnology in Q2 2018 and held it in 2 quarters.
  • Ghost Tree Capital's PDS Biotechnology position peaked at $820K in Q3 2018.
  • 31 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2018.

Based on Ghost Tree Capital's 13F filing for Q4 2018, filed 14 Feb 2019.